CEO Stephane Bancel of Moderna (NASDAQ:MRNA) stated that no decision has been made on the provision of COVID-19 vaccines to the Chinese government. Bancel declined to respond when asked if Moderna had applied for the vaccines approval in China, but he did say that the firm was willing to supply and had the capacity.
The corporation is also considering building up facilities in Japan to manufacture mRNA-based products, according to Bancel, who was speaking in Tokyo at the time. According to a Moderna spokeswoman, those negotiations have already taken place, thus the company is unable to comment on whether they are still ongoing.
Potential growth opportunities impacting on Moderna stock price?
This winter, there is roughly a 20% chance that a problematic strain of the virus may appear, according to Bancel, who added that this was not the worst-case situation. Speaking in Tokyo, Bancel revealed that Moderna was thinking about constructing factories there to create mRNA-derived goods.
The Future Is Bright for Moderna, So Buy It Now
China continues to lock down significant portions of society and carry out widespread testing in an effort to obliterate the coronavirus as the rest of the globe increasingly relaxes COVID restrictions. It relies on a number of domestically manufactured shots and has not approved any imported COVID vaccinations.
On September 12, the Omicron-targeting bivalent COVID-19 booster vaccine from MRNA received approval from Japans Ministry of Health, Labour, and Welfare. The vaccine candidate Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax), which targets the Omicron variant BA.1.
Last month, Moderna filed a lawsuit against Pfizer Inc (NYSE:PFE) and its collaborator BioNTech SE (22UAy.DE) for violating its patent during the creation of the first COVID vaccine to receive approval in the United States.
Featured Image- Megapixl @ Ralfliebhold
Author: Jowi Kwasu
Market Jar Media Inc.
#170 – 422 Richards Street
Vancouver, BC, Canada
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Opinion Bulletin journalist was involved in the writing and production of this article.